Leukemia Therapeutics Global Market Report 2024

Leukemia therapeutics refer to treatments used to address an aggressive malignancy characterized by an excessive presence of myeloblasts, immature white blood cells, in the blood or bone marrow. The choice of treatment for leukemia depends on factors such as age, overall health, the specific type of leukemia, its current state within the body, and other relevant considerations.

The primary types of treatments in leukemia therapeutics include chemotherapy, immunotherapy, targeted therapy, and other specific treatments. Immunotherapy involves stimulating the body's immune system to recognize and eliminate malignant cells. This approach is applied to treat various types of leukemia, including acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, using both small molecules and biologics. End users of leukemia therapeutics include hospitals, homecare settings, specialty clinics, and other relevant healthcare providers.

The leukemia therapeutics market research report is one of a series of new reports that provides leukemia therapeutics market statistics, including leukemia therapeutics industry global market size, regional shares, competitors with a leukemia therapeutics market share, detailed leukemia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the leukemia therapeutics industry. This leukemia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The leukemia therapeutics market size has grown strongly in recent years. It will grow from $16.55 billion in 2023 to $17.78 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth observed during the historic period can be attributed to several factors, including the increase in the geriatric population, advancements in diagnostics leading to early detection of leukemia, a rise in the prevalence of leukemia, growing investments in research and development, and the expansion of personalized medicine approaches.

The leukemia therapeutics market size is expected to see strong growth in the next few years. It will grow to $23.98 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The anticipated growth in the forecast period can be attributed to several factors, including the development of novel immunotherapies for leukemia, a growing focus on precision medicine in leukemia treatment, the expansion of indications for existing leukemia therapies, increased adoption of gene therapies, and advances in supportive care for leukemia patients. Major trends expected in the forecast period include the integration of biomarker-driven approaches, the rise of combination therapies for enhanced efficacy, an emphasis on minimal residual disease monitoring, increasing use of CAR-T cell therapies, and exploration of targeted therapies based on specific leukemia subtypes. These trends collectively contribute to the positive trajectory of the leukemia therapeutics market.

The leukemia therapeutics market is experiencing growth driven by the increasing prevalence of leukemia, a type of blood cancer characterized by uncontrolled blood cell growth originating in the bone marrow. The global accessibility of medical treatment for leukemia patients and the expanding array of treatment options contribute to the growing demand for leukemia therapeutics. As of January 2023, the American Cancer Society projects around 59,610 new cases of leukemia and approximately 23,710 leukemia-related deaths in the United States. Additionally, an estimated 20,380 new cases of acute myeloid leukemia (AML) and approximately 11,310 AML-related deaths are expected in the same year. Thus, the escalating incidence of leukemia is a significant factor propelling the growth of the leukemia therapeutics market.

The growth of the geriatric population is anticipated to further fuel the expansion of the leukemia therapeutics market. The term 'geriatric population' pertains to individuals aged 65 and older. With the aging of the population, the heightened risk of developing leukemia and related blood disorders increases, leading to a greater demand for leukemia therapeutics. According to a report by the World Health Organization (WHO) in October 2022, it is projected that one in six people globally will be 60 or older by 2030, and by 2050, the worldwide population of individuals aged 60 and older will reach 2.1 billion. Consequently, the rise in the geriatric population serves as a driving force for the growth of the leukemia therapeutics market.

A new trend gaining traction in the leukemia therapeutics market is the adoption of combination therapies. In combination therapies, two or more treatment modalities are explored, often in conjunction with immunotherapies or targeted therapies, with the goal of delivering long-term survival benefits not achievable through current approaches. For example, in September 2021, the clinical research team at Dana-Farber Cancer Institute reported the effectiveness of a combination therapy involving three molecularly targeted drugs - BCL-2 inhibitor (venetoclax), second-generation BTK inhibitor (acalabrutinib), and CD20 inhibitor (obinutuzumab) - against chronic lymphocytic leukemia (CLL).

Major companies operating in the leukemia therapeutics market are focusing on innovation by developing groundbreaking products such as Chimeric Antigen Receptor T-cell (CAR-T) therapies to expand their customer base, boost sales, and increase revenue. CAR-T therapy represents a revolutionary form of immunotherapy for treating certain types of cancer. In October 2021, Kite Pharma received U. S. Food and Drug Administration (FDA) approval for Tecartus, the first and only CAR-T cell therapy authorized for use in adults aged 18 and above with B-cell precursor acute lymphoblastic leukemia (ALL). Tecartus, an autologous CAR-T therapy targeting CD19, employs the XLP manufacturing process, a critical step in specific B-cell malignancies.

In November 2021, Pfizer Inc. acquired Trillium Therapeutics for approximately $2.22 billion, enhancing its oncology portfolio with next-generation immunotherapies. Trillium Therapeutics, based in Canada, focuses on developing cancer treatment therapies.

Major companies operating in the in the leukemia therapeutics market report are Novartis International AG, AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche AG, Sanofi S. A., Agios Pharmaceuticals, Amgen Inc., Argenx SE, Astellas Pharma Inc., BioLineRx Ltd., Celgene Corporation, Cellerant Therapeutics Inc., Daiichi Sankyo Company Limited, Forma Therapeutics Inc., Gilead Sciences Inc., Incyte Corporation, Jazz Pharmaceuticals plc, Johnson & Johnson, Mirati Therapeutics Inc., Molecular Templates Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Seattle Genetics Inc., Stemline Therapeutics Inc., Sunesis Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, TG Therapeutics Inc., Trovagene Inc., Akebia Therapeutics Inc., Allogene Therapeutics Inc., Blueprint Medicines Corporation, Karyopharm Therapeutics Inc., Verastem Oncology Inc.

North America was the largest region in the leukemia therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukemia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the leukemia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The leukemia therapeutics market includes revenues earned by entities by by killing fast-growing cancer cells. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.